It has been reported that the influx of abnormal tau into CSF and blood may be a result of aging-related disruption of the blood–brain barrier, and that specific phosphorylation sites of tau in CSF and plasma may be useful as biomarkers to identify the early stage of tauopathies [149, 210, 278]. The gene discussed is MAPT; the disease is tauopathy.